New hope for Tough-to-Treat blood cancer: phase 3 trial tests experimental pill
NCT ID NCT06776952
Summary
This study is testing whether an experimental pill called XNW5004 works better than an existing drug (Chidamide) for patients whose peripheral T-cell lymphoma has come back or hasn't responded to prior treatment. It's a Phase 3 trial enrolling 120 adults who have already tried at least one other treatment. The main goal is to see if XNW5004 can keep the cancer from getting worse for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Friendship Hospital,Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.